Efficacy and safety of oncoplastic surgery plus drug therapy for chronic tuberculous granulomatous mastitis

M. E. Pinto Paz, L. Bueno Lazo, D. Carrera Palao, D. F.Pinto Ruiz, M. R. Huaman, A. M. Quispe

Producción científica: Artículo CientíficoArtículo originalrevisión exhaustiva

1 Cita (Scopus)


BACKGROUND: Chronic tuberculous granulomatous mastitis (CTGM) is a rare form of tuberculosis (TB) treated primarilywith anti-TB drugs.Oncoplastic surgery (OS) has been proposed as adjuvant therapy for CTGM. METHOD: We followed for 1 year every CTGM patients and assessed the efficacy (defined as non-recurrence and no need for corticosteroids) and safety attributable to the standard anti-TB drugs therapy with and without OS. RESULT S: We analysed 128 CTGM cases, including 78 (61%) treated with OS plus anti-TB drugs and 50 (39%) with anti-TB drugs only. We observed a significantly higher efficacy among those exposed vs. unexposed to OS (100% vs. 92%; prevalence ratio [PR] 1.09, 95% CI 1.00-1.18), with no difference in the number of complications (21% vs. 8%; PR 2.56, 95% CI 0.91- 7.26). We also observed that the incidence of postoperative complications decreased by 50% when OS was postponed from after Month 1 to after completing Month 2 of anti-TB drugs treatment (19% to 8%; PR 0.46, 95% CI 0.13-1.62). CONCLUS ION: OS appears to represent an efficacious and safe adjuvant therapy when combined with anti-TB drugs in the treatment of CTGM patients, but clinical trials are needed to prove this observation.

Idioma originalInglés estadounidense
Páginas (desde-hasta)585-590
PublicaciónInternational Journal of Tuberculosis and Lung Disease
EstadoIndizado - 1 jun. 2020

Nota bibliográfica

Publisher Copyright:
© 2020 International Union against Tubercul. and Lung Dis.. All rights reserved.


Profundice en los temas de investigación de 'Efficacy and safety of oncoplastic surgery plus drug therapy for chronic tuberculous granulomatous mastitis'. En conjunto forman una huella única.

Citar esto